Latest Bristol-Myers Squibb Stories
Three new studies presented today at the International Liver CongressTM 2014 have helped clarify the optimal use of combination therapy with peginterferon and nucleoside analogues (NUCs) to achieve the best treatment outcomes in patients with chronic hepatitis B (CHB).
SAN DIEGO, April 7, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc.
SAN DIEGO, April 4, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc.
SAN DIEGO, March 31, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc.
Innovative Physician Executive Brings Breadth of Healthcare Experience LOS ANGELES, March 31, 2014 /PRNewswire/ -- Health economics and policy authority Precision Health Economics
DUBLIN, March 28, 2014 /PRNewswire/ -- Dublin - Research and Markets ( http://www.researchandmarkets.com/research/cw7xqm/investigation) has announced the addition of the
LONDON, March 26, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:
NEW YORK, March 21, 2014 /PRNewswire/ -- Pomerantz LLP has filed a class action lawsuit against The Medicines Company ("Medicines" or the "Company") (NASDAQ: MDCO) and certain of its officers.
BUFFALO, N.Y., March 19, 2014 /PRNewswire/ -- Kinex Pharmaceuticals announced today to having received regulatory and ethics approvals to initiate the first clinical study of an oral
- Monstrous in size or character; huge; prodigious; monstrously perverse, savage, cruel, etc.